Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line

被引:10
|
作者
Rhee, MS
Schneider, E
机构
[1] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA
[2] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA
关键词
drug resistance; methotrexate; breast cancer resistance protein; polyglutamylation; folate metabolism;
D O I
10.1016/j.bcp.2004.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Accumulation of methotrexate (MTX) and its polyglutamates (PGs) has been recognized as an important factor in MTX efficacy. We have previously described a multidrug-resistant human breast cancer cell line, MCF7/MX, that exhibits reduced accumulation of total MTX as well as MTX-PGs, and that is resistant to continuous MTX exposure [Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, et al. Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is due to enhanced energy-dependent drug efflux. Cancer Res 2000;60:3514-21]. These cells express high levels of the breast cancer resistance protein (BCRP/ABCG2) that has been shown to actively transport MTX and short-chain MTX-PGs in vitro. However, the effect of BCRP on MTX-PG accumulation in intact cells was unclear. Here, we show that MTX transport by BCRP is required for the observed lower levels of MTX-PGs in the resistant cells. When BCRP was inhibited with fumitremorgin C, or in cells expressing a mutated form of BCRP that is unable to transport MTX, MTX-PG accumulation was similar or even higher than that in the parental cells that do not express BCRP. Concomitantly, there was increased inhibition of thymidylate synthase. It had previously been suggested that BCRP-mediated efflux of MTX-PGs contributed to the reduced MTX-PG accumulation. However, we found no evidence of BCRP-mediated efflux of MTX-PGs from intact cells, suggesting that direct efflux of MTX-PGs does not play a major role in MTX resistance. Together, these data show that BCRP overexpression can cause a reduction in total MTX accumulation as well as a reduction in the proportion of long-chain MTX-PGs. In contrast, BCRP overexpression did not affect natural folate accumulation or the relative distribution of folylpolyglutamates in the resistant, as compared to the parental, cells. Thus, it appears that BCRP overexpression affects the metabolism of the antifolate MTX, but not that of natural folates, although indirect effects cannot be excluded. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 50 条
  • [21] Aryl Hydrocarbon Receptor Is a Transcriptional Activator of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
    Tan, Kah Poh
    Wang, Bernice
    Yang, Mingdong
    Boutros, Paul C.
    MacAulay, Jane
    Xu, Haibo
    Chuang, Andrew I.
    Kosuge, Kazuhiro
    Yamamoto, Mika
    Takahashi, Shinichiro
    Wu, Alex M. L.
    Ross, Douglas D.
    Harper, Patricia A.
    Ito, Shinya
    MOLECULAR PHARMACOLOGY, 2010, 78 (02) : 175 - 185
  • [22] In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2)
    Ding, Yi-Lung
    Shih, Yu-Hsuan
    Tsai, Fu-Yuan
    Leong, Max K.
    PLOS ONE, 2014, 9 (03):
  • [23] Contribution of different microRNAs to the regulation of breast cancer resistance protein (BCRP/ABCG2)
    Li, Xin
    Pan, Yuzhuo
    Yu, Aiming
    DRUG METABOLISM REVIEWS, 2009, 41 : 174 - 175
  • [24] HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2)
    Gupta, A
    Zhang, Y
    Unadkat, JD
    Mao, QC
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (01): : 334 - 341
  • [25] Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2)
    Allen, JD
    Schinkel, AH
    MOLECULAR CANCER THERAPEUTICS, 2002, 1 (06) : 427 - 434
  • [26] Characterizing the expression and interindividual variability of human breast cancer resistance protein (BCRP/ABCG2) in renal cell carcinoma
    Reustle, A.
    Renner, O.
    Kruck, S.
    Rausch, S.
    Nies, A. T.
    Hennenlotter, J.
    Fend, F.
    Bedke, J.
    Schwab, M.
    Schaeffeler, E.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S7 - S7
  • [27] Effect of capsaicin on breast cancer resistance protein (BCRP/Abcg2) and pharmacokinetics of probe substrates in rats
    Chen, Fen
    Wang, Liu
    Zhai, Xuejia
    Wang, Nanxi
    Qin, Yanjie
    Zhu, Chaoran
    Wu, Sanlan
    Lu, Yongning
    XENOBIOTICA, 2022, 52 (02) : 209 - 217
  • [28] Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the Oocytes of Xenopus laevis
    Nakanishi, T
    Doyle, LA
    Hassel, B
    Wei, YT
    Bauer, KS
    Wu, SL
    Pumplin, DW
    Fang, HB
    Ross, DD
    MOLECULAR PHARMACOLOGY, 2003, 64 (06) : 1452 - 1462
  • [29] Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators
    Zattoni, Ingrid Fatima
    Delabio, Leticia Carani
    Dutra, Julia de Paula
    Kita, Diogo Henrique
    Scheiffer, Gustavo
    Hembecker, Marina
    Pereira, Giovana da Silva
    Moure, Vivian Rotuno
    Valdameri, Glaucio
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 237
  • [30] The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk
    Jonker, JW
    Merino, G
    Musters, S
    van Herwaarden, AE
    Bolscher, E
    Wagenaar, E
    Mesman, E
    Dale, TC
    Schinkel, AH
    NATURE MEDICINE, 2005, 11 (02) : 127 - 129